Martino Elena, Thakur Shruti, Kumar Arun, Yadav Ashok Kumar, Boschi Donatella, Kumar Deepak, Lolli Marco
Department of Science and Drug Technology, University of Turin, via Pietro Giuria 9, Turin, 10125, Italy.
Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan-173229, India.
Mini Rev Med Chem. 2024;24(22):1983-2007. doi: 10.2174/0113895575303614240527093106.
Cancer remains a primary cause of death globally, and effective treatments are still limited. While chemotherapy has notably enhanced survival rates, it brings about numerous side effects. Consequently, the ongoing challenge persists in developing potent anti-cancer agents with minimal toxicity. The versatile nature of the quinazoline moiety has positioned it as a pivotal component in the development of various antitumor agents, showcasing its promising role in innovative cancer therapeutics. This concise review aims to reveal the potential of quinazolines in creating anticancer medications that target histone deacetylases (HDACs).
癌症仍然是全球主要的死亡原因，有效的治疗方法仍然有限。虽然化疗显著提高了生存率，但它会带来许多副作用。因此，开发毒性最小的强效抗癌药物的挑战依然存在。喹唑啉部分的多功能性使其成为各种抗肿瘤药物开发中的关键成分，显示出其在创新癌症治疗中的潜在作用。这篇简短的综述旨在揭示喹唑啉在开发靶向组蛋白脱乙酰酶（HDAC）的抗癌药物方面的潜力。
